STARODUBOV, V.I.,
MARCZAK, L.B.,
VARAVIKOVA, E.,
BIKBOV, B.,
ERMAKOV, S.P.,
GALL, J.,
GLENN, S.D.,
GRISWOLD, M.,
IDRISOV, B.,
KRAVCHENKO, M.,
LIOZNOV, D.,
LOYOLA, E.,
RAKOVAC, I.,
VLADIMIROV, S.K.,
VLASSOV, V.,
MURRAY, C.J.L.,
NAGHAVI, M (2018) to behavioural risk factors, including alcohol use,
drug use, and smoking.
Interpretation Trends in mortality
-colon cancers
drugs are urgently needed. In this study, we investigated the anti-metastatic property EnDuo, a
AKHMADIEV, N.S.,
AKHMETOVA, V.R.,
IBRAGIMOV, A.G.,
GALIMOVA, A.M.,
GALIMOVA, R.A.,
AGLETDINOV, E.F.,
KATAEV, V.A.,
KHAIRULLINA, V.R. (2019) . The tested compound is comparable, in terms of its activity to the hepatoprotective
drug SAM according
, increasing number of invasive diagnostic, and treatment methods. However, the
drugs traditionally used
Мироненкова, Ж.В.,
Муссави, М.Э.,
Давлетьянова, А.Ф.,
Mironenkova, Zh.V.,
Moussawi, M.A.,
Davletianova, A.F. (2017) with antiretroviral
medicines is given. The holders of marketing authorization
of these
drugs in Russia are indicated
Chatelain, Pierre,
Malievskiy, Oleg,
Radziuk, Klaudziya,
Senatorova, Ganna,
Abdou, Magdy O.,
Vlachopapadopoulou, Elpis,
Skorodok, Yulia,
Peterkova, Valentina,
Leff, Jonathan A.,
Beckert, Michael (2017) unrelated to the study
drug. Injection site tolerance was good. One TransCon GH subject developed a low